Preclinical evaluation of the pharmacokinetics, brain uptake and metabolism of E121, an antiepileptic enaminone ester, in rats.
The present study describes the brain uptake, pharmacokinetics and metabolism of an anticonvulsant enaminone ester E121, which belongs to a new and active series of compounds with potential in vivo anticonvulsant activity in rodent models, in rats. A single dose of E121 was administered i.p. to male Sprague Dawley rats at 10 mg E121/kg body weight. Cohorts of animals (n=3) were killed at varying times over 0-24 h to collect plasma and brain samples. Urinary excretion of E121 was studied in a separate group of five rats at the same dose. A validated HPLC method was used to quantify E121 and its metabolites in plasma, brain and urine. LC-MS/MS was used to characterize the metabolites. The plasma and brain Cmax of 11.0+/-3.0 mg/l and 10.4+/-1.4 mg/kg, respectively, were observed for E121 at 15 min post dose and they declined in a mono-exponential fashion. The plasma Cl/F and t1/2 were 0.57 l/h/kg and 0.75 h, respectively. The brain uptake ratio of E121 was 0.9. Mass spectral analysis of urine showed two major metabolites (m/z 280) and one minor metabolite (m/z 236) that were consistent with initial hydrolysis of the compound to the acid followed by further decarboxylation and appears to be the major route of elimination of E121. The rapid and moderate brain uptake of E121 correlates well with its potential anticonvulsant activity (ED50 3.0 mg/kg p.o. in rats). The brain uptake, pharmacokinetic and metabolic profile of E121 supports the need to further evaluate this compound for its potential as an antiepileptic.
Khurana
Manoj
M
Pharmacokinetics-Biopharmaceutics Laboratory, Department of Pharmaceutical Sciences, University of Maryland, School of Pharmacy, Baltimore, MD 21201, USA. mkhurana@rx.umaryland.edu
Salama
Noha N
NN
Scott
Kenneth R
KR
Nemieboka
Noble N
NN
Bauer
Kenneth S
KS
Eddington
Natalie D
ND
D000814:Aniline Compounds / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D000818:Animals; D000927:Anticonvulsants / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D019540:Area Under Curve; D001921:Brain / Q000378:metabolism*; D002853:Chromatography, Liquid; D003509:Cyclohexanecarboxylic Acids / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D006207:Half-Life; D007274:Injections, Intraperitoneal; D008297:Male; D013058:Mass Spectrometry; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D000814:Aniline Compounds; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; C483746:E 121 compound